Actively Recruiting
Phase 2a Multicenter Randomized Study of Targeted Therapies for Adults With Moderate to Severe Crohns Disease
Led by AbbVie · Updated on 2026-09-25
590
Participants Needed
255
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Crohns disease is a long-lasting condition causing severe inflammation in the digestive tract, mainly affecting the bowels. Symptoms include belly pain, diarrhea, tiredness, and weight loss. This study evaluates targeted therapies for adults with moderate to severe Crohns disease, aiming to understand their effectiveness and side effects. The trial is a Phase 2a randomized platform study involving about 590 participants worldwide. Participants will be randomly assigned to receive one of several treatments risankizumab, trosunilimab, lutikizumab, or ABBV-8736, administered either by injection under the skin or infusion into the vein. Some groups receive combination therapies involving different doses and delivery methods. A long-term extension allows risankizumab monotherapy for up to 72 weeks. Treatments are given at hospitals or clinics in scheduled visits. During the study, participants attend regular visits for medical assessments including blood tests, endoscopies, and questionnaires. Researchers monitor treatment effects, side effects, and disease activity using tools like endoscopic remission and clinical remission scores. Safety and adverse events are tracked up to approximately 96 weeks. Participants keep daily diaries and complete questionnaires to aid data collection.
CONDITIONS
Brief Title
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here